Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002570568 | SCV002953737 | uncertain significance | Neu-Laxova syndrome 2 | 2022-03-24 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with PSAT1-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.006%). This sequence change replaces phenylalanine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 364 of the PSAT1 protein (p.Phe364Ile). ClinVar contains an entry for this variant (Variation ID: 977069). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this missense change affects PSAT1 function (PMID: 32077105). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). |
Dudley Research Group, |
RCV001254589 | SCV001430569 | not provided | not provided | no assertion provided | research |